Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Relief Therapeutics Hldg Ag (OP: RLFTF )

5.450 -0.130 (-2.33%)
Streaming Delayed Price Updated: 9:30 AM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Relief Therapeutics Hldg Ag

< Previous 1 2 3 4 5 6 7 Next >
Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Relief Therapeutics Announces Executive Leadership Team Change
Via ACCESSWIRE
Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Via ACCESSWIRE
Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board
Via ACCESSWIRE
Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023
Via ACCESSWIRE
Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe
Via ACCESSWIRE
Relief Therapeutics Announces Executive Leadership Team Changes
Via ACCESSWIRE
Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)
Via ACCESSWIRE
Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting
Via ACCESSWIRE
Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA
Via ACCESSWIRE
Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars
Via ACCESSWIRE
Relief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis Bullosa
Via ACCESSWIRE
Relief Therapeutics Provides an Update on its Financing Strategy
Via ACCESSWIRE
Relief Announces U.S. Launch of PKU GOLIKE
Via ACCESSWIRE
Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S.
Via ACCESSWIRE
Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
Via ACCESSWIRE
Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission
Via ACCESSWIRE
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements
Via ACCESSWIRE
Relief Therapeutics to Participate in January Investor Meetings
Via ACCESSWIRE
Relief Therapeutics Announces Issuance of Shares from Authorized Capital
Via ACCESSWIRE
APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival
Via ACCESSWIRE
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission
Via ACCESSWIRE
Relief Therapeutics, NRx Pharma Settle Litigation Regarding COVID-19 Treatment Candidate
Via Benzinga
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements
Via ACCESSWIRE
Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. Further Extend their Stay of Pending Litigation to Provide Additional Time for the Parties to Finalize their Litigation Settlement
Via ACCESSWIRE
RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. Extend Their Stay of Pending Litigation to Provide Additional Time for The Parties to Finalize Their Settlement
Via ACCESSWIRE
Relief Therapeutics Files Amendment No. 2 to its Form F-6 Registration Statement with the U.S. Securities and Exchange Commission
Via ACCESSWIRE
Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer
Via ACCESSWIRE
Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa at Ann & Robert H. Lurie Children's Hospital of Chicago
Via ACCESSWIRE
Relief Reports Half-Year 2022 Results and Provides Corporate Update
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.